S798
Clinical - Lung
ESTRO 2026
5/16 pts developed local and/or distant progression during maintenance (2 pts local, 2 pts distant lesions – adrenal and brain – 1 pts both local and distant – pleura).Grade 3-4 PRAEs was 9 (6.4% of all AEs). Only one was immune-related while the remaining PRAEs were related to chemotherapy and none to RT. Median follow-up was 15.4 months. Median PFS for the entire cohort was 13.2 months (95% CI: 4.9 – 18.6), and median OS was 17.5 months (95% CI: 10.7 – 18.6). We performed an exploratory analysis showing that among the 16 patients who started maintenance median PFS was 18.6 months (95% CI: 12.8 – not reached) and median OS was not reached Conclusion: This report showed the feasibility and tolerability of this innovative approach. Early PFS and OS data are promising, especially for patients who completed the full treatment sequence. Keywords: NSCLC, immunotherapy, radiotherapy STEREOTACTIC BODY RADIOTHERAPY FOR LUNG OLIGO-METASTASES: INSIGHTS FROM A MULTI- INSTITUTIONAL EXPERIENCE Andrea D'Aviero 1 , Donato Pezzulla 2 , Marco Lucarelli 3 , Giulia de Pasquale 4 , Tamara Santone 4 , Carlos Alberto Cano Solórzano Cano 1 , Marica Ferro 2 , Maria Taraborrelli 4 , Antonio Piras 5 , Valeria Venuti 5 , Giorgia de Gregorio 5 , Antonino Daidone 5 , Gabriella Macchia 2 , Francesco Deodato 2 , Domenico Genovesi 1 1 Department of Medical, Oral and Biotechnological Sciences, "G. D’Annunzio” University of Chieti - Pescara, Chieti, Italy. 2 Radiation Oncology Unit, Responsible Research Hospital, Campobasso, Italy. 3 Division of Radiation Oncology, European Institute of Oncology IRCSS, Milan, Italy. 4 Department of Radiation Oncology, "S.S. Annunziata" Chieti Hospital, Chieti, Italy. 5 UO Radioterapia Oncologica, Villa Santa Teresa, Palermo, Italy Purpose/Objective: This study aimed to evaluate the oncological outcomes of Stereotactic Body Radiotherapy (SBRT) in patients with pulmonary oligo-metastatic disease (OMD). The primary objective was to assess SBRT’s effectiveness in preserving systemic therapeutic options by delaying further treatment lines, reducing therapy-related toxicity, and maintaining disease control. Material/Methods: Digital Poster 2686 This multi-institutional retrospective study included data from patients with lung OMD treated with SBRT from 2010 to 2024 across three institutions. Eligibility criteria were: histologically confirmed primary cancer, radiologic evidence of OMD at restaging, and no recent change in systemic therapy line prior to SBRT.
Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy. 4 Department of Medicine, University Milano-Bicocca, Milano, Italy. 5 Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. 6 Department of Medicine and Surgery, University Milano-Bicocca, Milano, Italy. 7 Radiation Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. 8 Biostatistics and Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 9 Department of Medical Sciences and Infective Disease, Unit of Respiratory Disease, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 10 Department of Medicine and Technological Innovation, University of Insubria, Varese, Italy. 11 Department of Oncology, University of Milan, Milano, Italy. 12 Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Purpose/Objective: PACIFIC regimen is the gold standard of care for unresectable, stage III non-small cell lung cancer (NSCLC). The DEDALUS trial is a Phase 2, open-label, multicenter study enrolling patients who are unsuitable for cCRT but eligible for sequential CRT plus immunotherapy. Its objective is to evaluate the safety and activity of induction chemo-immunotherapy followed by a reduced-dose radiotherapy (RT) with durvalumab and maintenance durvalumab. This report presents the final safety data along with preliminary findings on progression-free survival (PFS) and overall survival (OS) and pattern of disease progression. Material/Methods: Patients (pts) had stage IIIA-C NSCLC, PD-L1 all comers
and no oncogene-driven. They were judged unresectable and unsuitable for cCRT after
multidisciplinary evaluation. After three cycles of chemo-durvalumab, responders received thoracic RT (45 Gy in 15 fractions) with durvalumab, then continued durvalumab for up to 12 months or until disease progression. The primary endpoint was safety, assessed by the incidence of Grade 3 and 4 possibly related adverse events (PRAEs) within six months. Secondary endpoints included PFS and OS. Results: Between February 2022 and August 2024, 28 patients were screened, and 25 enrolled. Patients’ characteristics at baseline: median age: 70 years (range, 51-84); male (72%), all former or current smokers, PD-L1 positive (60%). All patients had comorbidities. 18/25 pts showed no disease progression after induction phase and received subsequent RT; 16/25 received at least one dose of durvalumab post-RT. 4/25 patients was progressors during induction phase: 1 local, 2 new lesions (brain and lymph nodes), 1 both; 1/18 pts underwent local progression post immune-radiotherapy phase and
Made with FlippingBook - Share PDF online